2 years of Androgen inhibition.
    9/10/2025

    From the encyclopedia
    Finasteride โ†’

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride โ†’

    Heavy duty finasteride that comes with higher risks

    Spironolactone โ†’

    powerful topical and oral anti-androgen used mostly by women

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    ๐Ÿ’Š Finasteride (oral) 1mg daily 2 years
    ๐Ÿ’Š Dutasteride (oral) 0.5mg 2x/week since February 2025
    ๐Ÿ’Š Dutasteride (oral) 0.5mg daily since April 2025
    ๐Ÿ’Š Finasteride (oral) 5mg daily since April 2025
    ๐Ÿ’Š Spironolactone (oral) 100mg daily 2 months
    the tone is mixed with mixed results.

    Other terms

    A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.
    View this post in the Community โ†’

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Antiandrogens and Androgen Inhibitors in Dermatologic Treatments

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
      Androgens in Women: Hormone-Modulating Therapies for Androgen-Mediated Cutaneous Disorders

      research Androgens in women

      34 citations , October 2018 in “Journal of The American Academy of Dermatology”
      This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.
      Controversies in Polycystic Ovary Syndrome

      research Controversies in Polycystic Ovary Syndrome

      February 2018 in “InTech eBooks”
      This article discusses the unclear aspects of diagnosing and treating polycystic ovarian syndrome and emphasizes a multidisciplinary approach but reports no clinical results.
      The Hormonal Background of Hair Loss in Non-Scarring Alopecias

      research The Hormonal Background of Hair Loss in Non-Scarring Alopecias

      February 2024 in “Biomedicines”
      This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.
      Treatment of Hyperandrogenism in Polycystic Ovary Syndrome

      research Treatment of hyperandrogenism in polycystic ovary syndrome

      1 citations , October 2010 in “Cambridge University Press eBooks”
      This review discusses strategies for managing dermatological symptoms of hyperandrogenism in PCOS by reducing androgen levels and actions, and reports no new clinical results.